Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

Renal cell carcinoma: review decision - December 2014 information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 62 KB)

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 62 KB)

TA178 Renal cell carcinoma: review decision - May 2012 information

TA178 Renal cell carcinoma: review proposal - March 2012 information

Appendix A: provisional matrix of stakeholders (MSWord 62 KB)

Appendix B: proposal paper presented to the Institute's guidance executive (PDF 179 KB)

NICE issues guidance on the use of other treatment options for renal cancer (PDF 33 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: notice of appeal hearing information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appeal announcement information

Roche

Roche: appeals received (PDF 74 KB)

Roche: initial scrutiny letter (PDF 24 KB)

Roche: response to scrutiny letter (PDF 47 KB)

Roche: final scrutiny letter (PDF 15 KB)

Wyeth

Wyeth: appeals received (PDF 89 KB)

Wyeth: initial scrutiny letter (PDF 25 KB)

Wyeth: response to scrutiny letter (PDF 79 KB)

Wyeth: final scrutiny letter (PDF 18 KB)

Wyeth: clarification letter (PDF 60 KB)

Wyeth: response to clarification letter (PDF 14 KB)

James Whale Fund for Kidney Cancer

James Whale Fund for Kidney Cancer: appeals received (PDF 66 KB)

James Whale Fund for Kidney Cancer: initial scrutiny letter (PDF 26 KB)

James Whale Fund for Kidney Cancer: response to scrutiny letter (PDF 105 KB)

James Whale Fund for Kidney Cancer: final scrutiny letter (PDF 16 KB)

Rarer Cancers Forum and Macmillan Cancer Support

Rarer Cancers Forum and Macmillan Cancer Support: appeals received (PDF 46 KB)

Rarer Cancers Forum and Macmillan Cancer Support: initial scrutiny letter (PDF 27 KB)

Rarer Cancers Forum and Macmillan Cancer Support: response to scrutiny letter (PDF 17 KB)

Rarer Cancers Forum and Macmillan Cancer Support: final scrutiny letter (PDF 18 KB)

Renal cell carcinoma: appeal decision (PDF 72 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final appraisal determination (PDF 254 KB)

Response to consultee, commentator and public comments on the first ACD and comments from website consultation (PDF 286 KB)

Response to consultee, commentator and public comments on the second ACD and comments from website consultation (PDF 441 KB)

Consultee and commentator comments on the ACD

Bayer (PDF 45 KB)

Department of Health (PDF 7.8 KB)

Macmillan and Rarer Cancers forum (PDF 54 KB)

NHS Quality Improvement Scotland (PDF 9.9 KB)

Roche (PDF 119 KB)

Royal College of Nursing (PDF 19 KB)

Wyeth (PDF 122 KB)

Expert comments on the ACD

David Chao (PDF 11 KB)

Bill Savage (PDF 28 KB)

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination information

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination information

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma: final appraisal determination (PDF 155 KB)

Update on renal cell carcinoma drugs (PDF 15 KB)

Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 475 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation 2

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document 2 information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report

Consultee and commentator comments on the first ACD

Bayer (PDF 29 KB)

British Uro-oncology Group (BUG) (PDF 70 KB)

Cancer Research UK (PDF 39 KB)

Kidney cancer UK/James Whale fund for kidney cancer (PDF 70 KB)

Macmillan and Rarer Cancers Forum (PDF 42 KB)

National Kidney Federation (PDF 26 KB)

NHS Cambridgeshire (PDF 29 KB)

NHS Quality Improvement Scotland (PDF 17 KB)

Novartis (PDF 20 KB)

Pfizer (PDF 331 KB)

Royal College of Physicians (PDF 46 KB)

Roche (PDF 48 KB)

Welsh Assembly Government (PDF 54 KB)

Wyeth (PDF 85 KB)

Wyeth 2 (PDF 22 KB)

External expert comments on the appraisal consultation document

Dr David Chao (PDF 24 KB)

Patient expert (PDF 17 KB)

Bill Savage (PDF 20 KB)

Report to the Appraisal Committee summarising comments (received by letter and email) on the appraisal consultation document - prepared by the Patient and Public Involvement Programme (PPIP) and Enquiry Handling team, September 2008 (PDF 1014 KB)

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic and economic evaluation - addendum to the report submitted on 2 May 2008 - prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter (PDF 156 KB)

Extra work on bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma - prepared by Decision Support Unit (PDF 133 KB)

First appraisal consultation document (PDF 233 KB)

Response from the Assessment Group to comments on the Assessment report (PDF 210 KB)

Consultee and commentator comments on the extra work consultation

Bayer (PDF 50 KB)

British Uro-oncology Group (PDF 93 KB)

Novartis (PDF 7.7 KB)

Pfizer (PDF 35 KB)

Roche (PDF 185 KB)

Royal College of Nursing (PDF 20 KB)

Royal College of Physicians (PDF 39 KB)

Wyeth (PDF 59 KB)

Extra work done by the Assessment Group (PenTAG) and the Decision Support Unit (DSU) on new data received (PDF 711 KB)

External expert comments received on the extra work consultation

Pat Hanlon (PDF 15 KB)

Dr David Chao (PDF 17 KB)

Bill Savage (PDF 22 KB)

Response from the DSU to comments on the extra work consultation (PDF 16 KB)

Revised analyses submitted by Bayer incorporating the sorafenib patient access scheme and new price of sorafenib (PDF 362 KB)

Extra work done by the DSU on the revised analyses submitted by Bayer (PDF 54 KB)

Department of Health approval for the Technology Appraisal Committee to consider patient access schemes submitted for sorafenib and sunitinib

Department of Health approval of sunitinib patient access scheme (PDF 25 KB)

Department of Health approval of patient access scheme for sorafenib (PDF 24 KB)

Consultee and commentator comments on the executable economic model

Pfizer (PDF 9.2 KB)

Bayer (PDF 17 KB)

DSU addendum to the review of Roche's request for parameter changes (PDF 17 KB)

Addendum to the pre-meeting briefing: end of life - a quantitative exploration (PDF 16 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: letter to consultees and commentators (PDF 39 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation document information

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report

Renal cell carcinoma - sunitinib: assessment report (PDF 1.82 MB)

Overview (PDF 353 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: consultee and commentator comments on the assessment report

Bayer (PDF 13 KB)

Kidney Research UK (PDF 27 KB)

NHS Quality Improvement Scotland (PDF 17 KB)

Pfizer (PDF 46 KB)

Pfizer 1 (PDF 128 KB)

Pfizer 2 (PDF 418 KB)

Roche (PDF 110 KB)

Royal College of Nursing (PDF 21 KB)

Royal College of Physicians (PDF 48 KB)

Wyeth (PDF 183 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: non-manufacturer submission

Cancer Backup (PDF 50 KB)

National Kidney Federation (PDF 99 KB)

Joint submission from Kidney Cancer UK and James Whale Fund for Kidney Cancer (PDF 48 KB)

Joint submission from NCRI Renal Clinical Studies Group/Royal College of Radiologists/Royal College of Physicians/Joint Collegiate Council for Oncology/Association of Cancer Physicians (PDF 69 KB)

Kidney Research UK (PDF 27 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: manufacturer submissions (executive summary only)

Bayer (PDF 38 KB)

Pfizer (PDF 83 KB)

Pfizer - addendum to submission (PDF 52 KB)

Roche (PDF 32 KB)

Wyeth (PDF 74 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: expert written personal statements

Chao (PDF 22 KB)

Hanlon (PDF 21 KB)

Savage (PDF 38 KB)

Patient Expert Statement (PDF 36 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final matrix (PDF 48 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final scope (PDF 35 KB)

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft matrix (PDF 50 KB)

Renal cell carcinoma - bevacizumab, sarofenib and sunitinib: draft scope (PDF 37 KB)

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: final protocol (PDF 191 KB)